Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment
- PMID: 22257044
- DOI: 10.1111/j.1742-1241.2011.02845.x
Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment
Abstract
In recent years, the role of PET imaging in the prediction of mild cognitive impairment (MCI) to Alzheimer's disease (AD) conversion has been the subject of many longitudinal studies. The purpose of this study was to perform a meta-analysis to estimate the diagnostic accuracy of (18) F-fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) and (11) C-Pittsburgh Compound B-positron emission tomography (PIB-PET) for prediction of short-term conversion to AD in patients with MCI. The MEDLINE and EMBASE databases were systematically searched for relevant studies. Methodological quality of the included studies was assessed. Sensitivities and specificities of PET in individual studies were calculated and meta-analysis was undertaken with a random-effects model. A summary receiver operating characteristic (SROC) curve was constructed with the Moses-Shapiro-Littenberg method. Heterogeneity was tested, and the presence of publication bias was assessed. Potential sources for heterogeneity were explored by assessing whether or not certain covariates significantly influenced the relative diagnostic odds ratio (DOR). Pooled estimates of sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR-), DOR and the SROC curve of each PET imaging were determined. A total of 13 research studies (seven FDG-PET and six PIB-PET) met inclusion criteria and had sufficient data for statistical analysis. FDG-PET pooled estimates had 78.7% sensitivity (95% CI, 68.7-86.6%),74.0% specificity (95% CI, 67.0-80.3%), 18.1 LR+(95% CI, 7.3-45.0) and 0.32 LR-(95% CI, 0.16-0.61); and PIB-PET pooled estimates had 93.5% sensitivity (95%CI, 71.3-99.9%), 56.2% specificity (95% CI, 47.2-64.8%), 2.01 LR+ (95% CI, 1.57-2.58) and 0.17 LR-(95% CI, 0.08-0.36). Overall DOR was 17.3 (95% CI, 5.08-59.2) for FDG-PET and 12.8 (95% CI, 5.35-30.54) for PIB-PET. Area under the SROC curve was 0.88 ± 0.05 for FDG-PET and 0.85 ± 0.04 for PIB-PET. The data from FDG-PET research studies had high heterogeneity and funnel plot suggested a publication bias. The diagnostic accuracy determined for both FDG-PET and PIB-PET in this meta-analysis suggests that they are potentially valuable techniques for prediction of progression in patients with MCI. Both have their advantages and their combined use is a promising option for prediction purposes depending on availability and experience.
© 2012 Blackwell Publishing Ltd.
Similar articles
-
Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected].Medicine (Baltimore). 2014 Dec;93(27):e150. doi: 10.1097/MD.0000000000000150. Medicine (Baltimore). 2014. PMID: 25501055 Free PMC article.
-
Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.J Nucl Med. 2016 Feb;57(2):204-7. doi: 10.2967/jnumed.115.163717. Epub 2015 Nov 19. J Nucl Med. 2016. PMID: 26585056
-
A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.J Alzheimers Dis. 2017;59(2):603-614. doi: 10.3233/JAD-170158. J Alzheimers Dis. 2017. PMID: 28671117
-
18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.Acta Radiol. 2012 Jul;53(6):615-27. doi: 10.1258/ar.2012.110603. Epub 2012 Jun 25. Acta Radiol. 2012. PMID: 22734080
-
Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis.J Gastroenterol Hepatol. 2018 Mar;33(3):576-582. doi: 10.1111/jgh.14015. J Gastroenterol Hepatol. 2018. PMID: 28994187
Cited by
-
Prognosis of Alzheimer's Disease Using Quantitative Mass Spectrometry of Human Blood Plasma Proteins and Machine Learning.Int J Mol Sci. 2022 Jul 18;23(14):7907. doi: 10.3390/ijms23147907. Int J Mol Sci. 2022. PMID: 35887259 Free PMC article.
-
The impact of genetic risk for Alzheimer's disease on the structural brain networks of young adults.Front Neurosci. 2022 Nov 30;16:987677. doi: 10.3389/fnins.2022.987677. eCollection 2022. Front Neurosci. 2022. PMID: 36532292 Free PMC article.
-
Treatment of Mild Cognitive Impairment.Curr Treat Options Neurol. 2015 Sep;17(9):372. doi: 10.1007/s11940-015-0372-3. Curr Treat Options Neurol. 2015. PMID: 26208489
-
Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use.CNS Drugs. 2015 Apr;29(4):313-30. doi: 10.1007/s40263-015-0237-z. CNS Drugs. 2015. PMID: 25948171 Review.
-
Application of Concordance Probability Estimate to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease.Biostat Epidemiol. 2017;1(1):105-118. doi: 10.1080/24709360.2017.1342187. Epub 2017 Jul 31. Biostat Epidemiol. 2017. PMID: 30854502 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous